JAJowita Adamczyk-Zostawa

Jowita Adamczyk-Zostawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jowita Adamczyk-Zostawa has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Can Vitamin D Supplementation Improve Inflammation in Relapsing-Remitting Multiple Sclerosis Patients?

    by Martyna Lis, Natalia Niedziela, Jowita Adamczyk-Zostawa, Krzysztof Wierzbicki, Zenon Czuba, Jolanta Zalejska-Fiolka, Wojciech Bartman, Agata Świętek, Monika Adamczyk-Sowa

    (1) Background: Studies indicate that vitamin D (VitD) may reduce inflammation in multiple sclerosis (MS). The aim of the study was to assess the effect of supplementation with different doses of VitD on inflammation in relapsing-remitting MS (RRMS) patients. (2) Methods: The effect of 6-month supplementation with different doses of oral VitD (2000 IU/day) in a high-dose group (HD, n = 23) and a low-dose group (15,960 IU/month) (LD, n = 29) on selected markers of inflammation was assessed in 52 RRMS patients. (3) Results: Females constituted the majority of participants (63.46%). The median age [years] was 39.5 [34.5–49.8] and 47 [40.0–55.0] in the HD and LD groups, respectively. Significant differences were observed in age (p = 0.028), body weight (p = 0.014) and height (p = 0.001) between the study groups. Considering the BMI, statistically significant differences were not found (p = 0.496). The median 25(OH)D concentration [ng/mL] increased from 23.023 [15.578–25.76] in the HD group and 28.318 [20.644–32.232] in the LD group to 29.819 [24.937–38.064] and 30.837 [25.382–36.789], respectively (p < 0.01), and the increase was significantly higher in the HD group (p = 0.01). Hypovitaminosis D was found in most patients (71.2%) initially, and serum VitD levels were still p < 0.01). A significant positive correlation was observed between 25(OH)D serum levels and sCD40L (R = 0.33; p < 0.05) and TNF-α (R = 0.28; p < 0.05), and a significant negative correlation was reported between 25(OH)D and IL-23 (R = −0.32; p < 0.01) at the beginning of the study. (4) Conclusions: In RRMS patients, the doses of VitD were probably too low to induce beneficial effects on inflammation. Further studies are warranted to determine the effect of VitD supplementation on inflammatory markers in MS patients.


  • Open Access

    Can Vitamin D Reduce Inflammation? The Influence of Supplementation on Selected Immunological Markers

    by Martyna Lis, Natalia Niedziela, Jowita Adamczyk-Zostawa, Jolanta Zalejska-Fiolka, Michał Błachut, Jarosław Szczygieł, Agata Świętek, Monika Adamczyk-Sowa

    There is increasing evidence that vitamin D (VitD) supplementation may reduce inflammation in individuals with multiple sclerosis (MS). The aim of this study was to evaluate the effect of different doses of VitD on selected markers of inflammation in patients with relapsing–remitting MS (RRMS). Participants were divided depending on the supplemented dose of VitD into a high-dose (2000 IU/d; HD) group and a low-dose (15,960 IU/month; LD) group (n = 23 and n = 29, respectively). The concentration of 25(OH)D and the levels of CXCL16, PTX3, ALCAM, IL-1RA, and OPG were measured initially and after six months of VitD supplementation in blood serum. A significant increase in the concentrations of CXCL16, PTX3, and OPG was observed during the study (p = 0.02, p = 0.01, and p < 0.01, respectively). Furthermore, a higher increase in PTX3 and OPG in the LD group was observed (p = 0.04 and p = 0.03, respectively). A significant positive correlation was observed between the 25(OH)D serum concentration and PTX3 (R = 0.28, p < 0.05) and OPG (R = 0.28, p < 0.05) only at the beginning of the study. In patients with RRMS, such doses of VitD might be too low to induce obvious beneficial effects on the pro-inflammatory and inflammatory balance.


  • Open Access

    Selective Upregulation of Interleukin 1 Receptor Antagonist and Interleukin-8 in Fuchs’ Endothelial Corneal Dystrophy with Accompanying Cataract

    by Rafał Fiolka, Edward Wylęgała, Michał Toborek, Jowita Adamczyk-Zostawa, Zenon P. Czuba, Adam Wylęgała

    (1) Background: Patients with Fuchs’ endothelial corneal dystrophy (FECD) may have coexisting cataracts and, therefore, may require a cataract surgery, which poses challenges due to potential endothelial cell damage. FECD is a degenerative eye disease of unclear etiology, with inflammatory cytokines maybe playing an important role in its development and progression. The present study aimed to investigate the cytokine profile in the aqueous humor of FECD eyes with cataract. (2) Methods: Fifty-two patients were included in the study, 26 with FECD + cataract and 26 with cataract as a control group. Samples of the aqueous humor were analyzed for pro- and anti-inflammatory cytokines using a Bio-Plex 200 system. (3) Results: Interleukin 1 receptor antagonist (IL-1Ra) and interleukin IL-8 levels were significantly higher in the aqueous humor of FECD + cataract patients compared to the control/cataract group. Moreover, the levels of anti-inflammatory IL-10 showed a strong trend to be higher in the FECD + cataract group compared to the control group. In contrast, there were no statistically significant differences in IL-1β, IL-6, IL-4, IL-10, IL-13, IL-17A, and tumor necrosis factor TNF-α between the groups. (4) Conclusions: Presented research contributes to a better understanding of FECD pathogenesis. Elevated levels of IL-1Ra and IL-8 may serve as a defense mechanism in people with FECD and coexisting cataract.


  • The level of cytokines in tears as a novel indicator of demyelinating diseases

    by Jowita Adamczyk-Zostawa, Adam Wylęgała, Martyna Lis, Jacek Zostawa, Rafał Fiolka, Edward Wylęgała, Monika Adamczyk-Sowa, Zenon Czuba

    A novel research objective is to identify new molecules in more readily accessible biological fluids that could be used in the diagnosis of multiple sclerosis (MS) and other demyelinating disorders. To compare the level of selected cytokines in tears between patients with MS or other demyelinating disorder and healthy controls. 84 patients with diagnosed MS during remission or with other demyelinating disease of the CNS and 70 healthy controls were enrolled in the study. Tears were collected without any stimulation and stored till the day of assessment. The concentration of selected cytokines was measured by the Bio-Plex Pro Human cytokine screening panel 27 cytokines assay according to the manufacturer's instructions. Statistical analysis was performed with Statistica 13. IL-1b level was significantly lower in the study group compared to the control group [3,6 vs 8.71, p < 0.001]. The same pattern was observed for IL-6 [3,1 vs 5.26, p = 0.027] and IL-10 [1,7 vs 10.92, p < 0.001] (Table 1). In the study group, IL-1RA (p = 0.015), IL-5 (p = 0.04), IL-9 (p = 0.014), and IL-15 (p = 0.037) showed significant correlations with age. In the total sample, IL-1Ra (p = 0.016) and IFN-g (p = 0.041) were significantly correlated with age, while in the control group, IL-8 (p = 0.09), MIP-1a (p = 0.009), and RANTES (p = 0.031) showed significant correlations. Our results show that MS and other demyelination diseases lead to decrease in the overall level of cytokines in tears. Further research is needed to determine the role of tear fluid in the assessment of demyelinating disorders like MS.


  • Open Access

    Occupational Exposure of Employees in a Multispecialty Hospital to Factors Causing Contact Dermatitis—A Questionnaire Study

    by Aneta Drozdowska, Piotr Drozdowski, Aleksander Jaworski, Anna Ryczek, Daniel Bula, Dawid Adamczyk, Jowita Adamczyk, Ada Łątkowska, Barbara Sławińska, Adam Reich

    Background and Objectives: Allergic contact dermatitis (ACD) is a serious health and socio-economic problem. Accurate and reliable assessment of exposure to ACD factors in the work environment would increase quality of life and work of employees. The aim of this study was to assess the level of exposure of workers of a multidisciplinary hospital to the factors causing ACD. Material and Methods: The proprietary OSDES-16 questionnaire was used. The effectiveness of the OSDES-16 was confirmed statistically. The study included 230 employees of the medical center in Polanica Zdrój, divided into groups. Results: The differences in the overall assessment of exposure between the individual groups in the OSDES-16 scale were statistically insignificant (p > 0.05). There was no significant correlation between the current workplace and the level of exposure to ACD (p > 0.05). The level of exposure to ACD in the group of employees with work experience in the current position for more than 10 years was significantly higher than those working less than 6 years (p < 0.05). Conclusions: Nurses, midwives and paramedics are the occupational group most exposed to the development of contact allergy related to exposure to factors present in the work environment. The seniority of more than 10 years in the current position was linked with a higher level of occupational exposure.

  • 167 Effects of different doses of vitamin D supplementation on immune, inflammatory and oxidative stress parameters in the blood serum of patients with multiple sclerosis – a review

    by Martyna Lis, Jowita Adamczyk-Zostawa, Monika Adamczyk-Sowa

    Multiple sclerosis is a chronic inflammatory disease of the central nervous system associated with demyelination and neurodegeneration. In recent years, vitamin D has gained attention in the medical community following suggestions that there is a correlation between the level of serum vitamin D and the risk of multiple sclerosis, disease progression and activity. The aim of this article was to review recent literature describing the effects of vitamin D supplementation on the immune, inflammatory and oxidative stress parameters in patients with multiple sclerosis. In clinical trials, vitamin D doses ranging from 800 IU/day to 14,000 IU/day were tested. Researchers noticed significant differences in the range of action of vitamin D. However, the overview of studies failed to yield a definite answer concerning an effective dose of vitamin D. We concluded that there was no clear evidence for the impact of vitamin D supplementation on inflammatory parameters in multiple sclerosis patients, even though studies show consistently that the vitamin has an influence on the immune system and contributes to a reduction of pro-inflammatory cytokines. What is more, little is still known about the effects of vitamin D supplementation on oxidative stress, especially with regard to the potential effective dose. Consequently, more research is needed to gain a better understanding of this issue. There is increasing evidence on the significant role of vitamin D in patients with multiple sclerosis but there are as yet no global recommendations regarding the benefits of vitamin D supplementation and the supplementation dose. It is necessary to conduct further studies on the influence of vitamin D on disease activity due to its potential role as an add-on therapy in this group of patients or even as a preventative measure.

  • Open Access

    The influence of sodium on pathophysiology of multiple sclerosis

    by Jacek Zostawa, Jowita Adamczyk, Paweł Sowa, Monika Adamczyk-Sowa

    Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the central nervous system, and is an important cause of disability in young adults. In genetically susceptible individuals, several environmental factors may play a partial role in the pathogenesis of MS. Some studies suggests that high-salt diet (>5 g/day) may contribute to the MS and other autoimmune disease development through the induction of pathogenic Th17 cells and pro-inflammatory cytokines in both humans and mice. However, the precise mechanisms of pro-inflammatory effect of sodium chloride intake are not yet explained. The purpose of this review was to discuss the present state of knowledge on the potential role of environmental and dietary factors, particularly sodium chloride on the development and course of MS.


  • Open Access

    Melatonin Acts as Antioxidant and Improves Sleep in MS Patients

    by Monika Adamczyk-Sowa, Krystyna Pierzchala, Pawel Sowa, Sebastian Mucha, Izabela Sadowska-Bartosz, Jowita Adamczyk, Marcin Hartel

    The relationship between the prevalence of multiple sclerosis (MS) and sunlight’s ultraviolet radiation was proved. Oxidative stress plays a role in the pathogenic traits of MS. Melatonin possesses antioxidative properties and regulates circadian rhythms. Sleep disturbances in MS patients are common and contribute to daytime fatigue. The aim of study was to evaluate 5 mg daily melatonin supplementation over 90 days on serum total oxidant status (TOS), total antioxidant capacity (TAC) and its influence on sleep quality and depression level of MS patients. A case–control prospective study was performed on 102 MS patients and 20 controls matched for age and sex. The Kurtzke’s Expanded Disability Status Scale, magnetic resonance imaging examinations, Athens Insomnia Scale (AIS), Beck Depression Inventory questionnaires were completed. Serum TOS and TAC levels were measured. We observed higher serum levels of TOS in all MS groups, while after melatonin treatment the TOS levels significantly decreased. The TAC level was significantly lower only in mitoxantrone-treated group and it increased after melatonin supplementation. A strong positive correlation between T1Gd(+) number lesions and TAC level in interferon-beta-1A group was observed. AIS group mean score above 6 defining insomnia were observed in interferon-beta-1B-group, glatiramer acetate-group and mitoxantrone-group: 6.62 ± 2.88, 8.45 ± 2.07, 11.1 ± 3.25, respectively. After melatonin treatment the AIS mean scores decrease in glatiramer acetate-group and mitoxantrone-group achieving 5.25 ± 1.14 and 7.08 ± 2.39, respectively (p < 0.05). Finding from our study suggest that melatonin can act as an antioxidant and improves reduced sleep quality in MS patients.